AMGN Amgen Inc
Company Analysis
Latest News
🟢 Amgen is trading 3.23% up today amid a defensive shift toward healthcare
Amgen is trading at $466.44, up 3.23%, amid a reported defensive shift toward healthcare as investors move away from AI-linked stocks; this is sector context,...
🟢 Amgen is trading 3.08% up in pre-market as investors shift from AI-linked stocks to healthcare
Amgen is trading $465.75, up 3.08%, in pre-market amid a defensive rotation toward healthcare as investors move away from AI-linked stocks. - Reports offer a...
Amgen Reports 58% Lower Death Risk With Imdelltra-Imfinzi Combo
Amgen said its drug Imdelltra (tarlatamab), combined with AstraZeneca’s immunotherapy Imfinzi, reduced the risk of death by 58% in patients with...
🟢 Amgen is trading 3.25% up after Tezspire met Phase 3 endpoints
Amgen is trading up 3.25% at $438.77 on October 20 after positive full Phase 3 CROSSING results for Tezspire in eosinophilic esophagitis. - The trial met...
🔴 Amgen is trading 6.17% down in after-hours trading with no confirmed new catalyst
Amgen is trading at $407.27, down 6.17% after hours, with no reliable report confirming a new company announcement or late-breaking event behind the decline. -...
🟢 Amgen is trading 3.26% up on October 15, 2026, after Tezspire met primary Phase 3 endpoints
Amgen is trading 3.26% up at $439.99 after positive Phase 3 CROSSING trial results for Tezspire in eosinophilic esophagitis. - The study met its primary...
🟢 Amgen Inc is trading 3.18% up
AMGN is trading at $425.98, up 3.18%.
Amgen Pits Monthly MariTide Against Ozempic in Phase 3 Trial
Amgen is advancing its competition with Novo Nordisk with a new Phase 3 trial of MariTide (maridebart cafraglutide), its long-acting diabetes and obesity drug....
🔴 Amgen is trading 3% down today as Novartis’ failed pelacarsen trial raises Lp(a) concerns
Amgen is trading 3.00% down at $400.68, as a same-day report linked weakness to rival-trial concerns. - The failed Phase 3 pelacarsen cardiovascular-outcomes...
🟢 Amgen is trading 3.11% up with no confirmed catalyst
Amgen is trading at $415.14, up 3.11% on October 7, 2026, with the reason for the intraday rise unconfirmed. - Available search results showed no clear...
🟢 Amgen is trading 5.5% up in pre-market with the cause unconfirmed
Amgen is trading 5.5% higher at $429.45 in pre-market, with the cause unconfirmed. - Available search results identify no fresh October 2 company announcement...
🔴 Amgen is trading 3.27% down with no confirmed same-day company-specific catalyst
Amgen is trading at $407.71, with a -3.27% change; no confirmed same-day company-specific catalyst was found. - Teva received FDA approval for DEGEVMA, a...
Amgen shares rise, reports successful trial for first-in-class Sjögren's treatment
Amgen announced positive topline results from its Phase 3 OASIZ 301 study for dazodalibep. The investigational treatment for Sjögren's disease met its primary...
🟢 Amgen is trading 3.18% up today on tarlatamab survival benefit
Amgen is trading 3.18% up now at $405.67 after favorable developments surrounding tarlatamab (Imdelltra), including a statistically significant Phase 3...
Amgen's Lung Cancer Drug Delivers a Survival Win — But Can It Justify a Sustained Rally Beyond Today's 4.4% Pop?
Shares of Amgen surged 4.4% to $410.35, capping a five-session streak that has added roughly $34 per share since September 15. The catalyst: a one-two punch of...
🟢 Amgen is trading 4.4% up in pre-market on FDA easing and positive Phase 3 results
Amgen is trading 4.4% up in pre-market at $410.35 after positive IMDELLTRA developments. - The FDA shortened monitoring for the first two doses to six to...
🟢 Amgen is trading 15.94% up today in after-hours trading amid broader market rally
Amgen is trading at $440.31, up 15.94%, with the broader market rally providing the clearest available context. • It closed the regular session at $379.78 on...
Amgen Lung Cancer Combo Boosts Survival in Phase 3 Trial
Amgen announced that its Phase 3 DeLLphi-305 study for lung cancer therapy IMDELLTRA met its primary endpoint. The trial evaluated IMDELLTRA in combination...
A Rival's Trial Failure Torpedoes Amgen Shares — But Is the Real Risk in the Pipeline or the Price Tag?
Shares of Amgen plunged 10.1% to $393.17 on Tuesday — erasing roughly $24 billion in market value — after a one-two punch: Novartis disclosed that its Phase 3...
🔴 Amgen is trading 10.08% down today after Novartis’s failed pelacarsen trial
Amgen is trading 10.08% down now at $393.17 after Novartis reported its Phase 3 pelacarsen trial failed to reduce cardiovascular events, raising uncertainty...